Associated Papers
Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques.
Xu N et al.
Bioorganic & Medicinal Chemistry Letters, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.
Schöffski P et al.
Esmo Open, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.
Orsi DL et al.
Rsc Medicinal Chemistry, 2025
Hinge binder modification into imidazopyridine for targeting actionable mutations of RET kinase.
Maturi A et al.
Rsc Medicinal Chemistry, 2025
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).
Armstrong D et al.
Expert Opinion on Therapeutic Patents, 2025
Design and Discovery of Novel Selective RET Inhibitors with High Central Nervous System Penetration, Enhanced Pharmacokinetics, and Pharmacodynamics.
Wang X et al.
Journal of Medicinal Chemistry, 2025
Design, synthesis and evaluation of (E)-1-(4-(2-(1H-pyrazol-5-yl)vinyl)phenyl) derivatives as next generation selective RET inhibitors overcoming RET solvent front mutations (G810C/R).
Xu M et al.
European Journal of Medicinal Chemistry, 2025
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations.
Hualong M et al.
Journal of Medicinal Chemistry, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Rearranged during transfection (RET) lung cancer - Update on targeted therapies.
Mullally WJ et al.
Lung Cancer (amsterdam, Netherlands), 2025
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
Zhang Q et al.
Journal of Medicinal Chemistry, 2025
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.
Hamidi S et al.
Thyroid : Official Journal of the American Thyroid Association, 2025
Overview of management and therapeutic advances in medullary thyroid cancer.
Jara MA et al.
Endocrine Oncology (bristol, England), 2025
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature.
Resuli B et al.
Frontiers in Oncology, 2025
BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models.
Qin F et al.
Frontiers in Pharmacology, 2025
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) Kinase.
Qiao JX et al.
Journal of Medicinal Chemistry, 2024
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Li W et al.
Signal Transduction and Targeted Therapy, 2024
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Wei X et al.
Cancer Letters, 2024
Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.
Maturi A et al.
Acs Medicinal Chemistry Letters, 2024
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF et al.
Drugs, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review.
Deng R et al.
Heliyon, 2024
Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment-Implications for Systemic Treatment.
Papachristos AJ et al.
Cancers, 2024
Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q et al.
Scientific Reports, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD et al.
Thyroid : Official Journal of the American Thyroid Association, 2024
Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
Clark L et al.
Cancers, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U et al.
Molecular Cancer Therapeutics, 2023
Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
Wu K et al.
European Journal of Medicinal Chemistry, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK et al.
Endocrine Pathology, 2023
Medullary thyroid cancer - An update.
Fugazzola L
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A et al.
Critical Reviews in Oncology/hematology, 2023
A comprehensive overview of the relationship between RET gene and tumor occurrence.
Zhao L et al.
Frontiers in Oncology, 2023
Targeting Gatekeeper Mutations for Kinase Drug Discovery.
Zhou Y et al.
Journal of Medicinal Chemistry, 2022
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
Acharya B et al.
Expert Opinion on Therapeutic Patents, 2022
MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K et al.
European Journal of Endocrinology, 2022